SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLZR:a potential 10 bagger?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: majaman1978 who wrote (47)5/28/1997 5:28:00 PM
From: Verkaylac   of 315
 
Candela's ScleroPLUS honored as one of 1997's most technically innovative products

Wednesday May 28 3:34 PM EDT

Company Press Release

Candela's ScleroPLUS honored as one of 1997's most technically innovative products

WAYLAND, Mass.--(BW HealthWire)--May 28, 1997--

Third Candela Product to Win Award

Candela Corporation (NASDAQ: CLZR ) announced today that it is a recipient of Photonics Spectra's Photonics Circle of Excellence Award in recognition of Candela's ScleroPLUS(tm), an advanced cosmetic and medical laser system. Photonics Spectra Magazine is a leading publication serving the laser and photonics industry and this award honors the 25 most technically innovative products of the year.

The ScleroPLUS offers the widest array of wavelengths available today for the treatment of all vascular lesions, including leg telangiectasia, facial spider veins, port wine stains, hemangiomas, rosacea, stretch marks, vulvodynia, scars, warts, and other vascular abnormalities.

``The response from dermatologists and plastic surgeons to the ScleroPLUS has been extremely gratifying,'' said James C. Hsia, Ph.D., Candela's senior vice president of research and the inventor of the ScleroPLUS. ``Not only have they embraced the treatment of leg veins, they are also reporting improved results, with fewer side effects, using the device on most types of vascular skin lesions.''

Candela has won the award in previous years for two other products: the SPTL-1 Vascular Lesion Laser and the MDL-1 LaserTripter.

``This is a true honor and a testament, I believe, to our research and development team, led by Dr. Hsia, and to our overall ability to continue to bring new, innovative, leading-edge technologies to the medical and personal care markets,'' said Gerard E. Puorro, the company's president and chief executive officer.

Candela Corporation develops, manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical problems using lasers, cryosurgery, and other proven technologies. In addition, the company is applying its capabilities and experience with skin care and related problems to develop a network of company-owned skin care centers and spas. Founded near Boston in 1970 as Candela Laser Corporation, Candela markets and services its products in over 40 countries from offices in the United States, Europe, and the Far East. For more information about Candela, visit the company's web site at clzr.com

This press release includes certain forward-looking statements. Any such statements are subject to risks that could cause the actual results to vary materially, including negative developments relating to unforeseen order cancellations or push-outs, Candela's strategic relationships, the impact of intense competition, and changes in the laser industry.

Contact:

Candela Corporation
Jane Smith
508-358-7637, x247
or
Stuart Pearlman & Co.
Stuart Pearlman
212-370-4940
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext